Rozainanee Mohd Zain

Rozainanee Mohd Zain

Auto-generated profile, based on publicly available information

Rozainanee Mohd Zain

Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Malaysia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
PDF file
RSRosaida Md Said
Rosaida Md Said
RZRozainanee Mohd Zain
Rozainanee Mohd Zain
HCHuan-Keat Chan
Huan-Keat Chan
SSShahrul Aiman Soelar
Shahrul Aiman Soelar
NRNorhayati Rusli
Norhayati Rusli
MHMuhammad Radzi Abu Hassan
Muhammad Radzi Abu Hassan
Approximately 2.5% of the Malaysian population is currently living with hepatitis C virus (HCV) infection. Yet, the public awareness of the disease is limited and under‐screening remains a major challenge. With the support of international non‐for‐profit organizations, the Ministry of Health in Malaysia recently launched a one‐week nationwide hepatitis C screening campaign in conjunction with the World Hepatitis Day. For the first time, the rapid diagnostic test (RDT) for HCV screening was introduced in public health institutions. This campaign involved 49 hospitals and 38 health clinics across the country, targeting the adult general population with unknown HCV infection status. Of the 11 382 participants undergoing the RDT, 1.9% were found to be positive for hepatitis C antibody (anti‐HCV) and were referred to on‐site medical departments or nearby hospitals for confirmatory testing and treatment. Men, the Malay ethnic group, intranasal and injection drug users and ex‐prisoners were shown to have higher odds of being positive for anti‐HCV. In addition to serving as a model to educate the general population about the disease, this campaign demonstrates the feasibility of decentralizing HCV screening, particularly by promoting the use of RDT, and linking the HCV‐infected patients to care in Malaysia.

29 August 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
NMNur Aida Laili Mislan
Nur Aida Laili Mislan
MCMarimuthu Citartan
Marimuthu Citartan
ASAmir Muhaimin Akmal Shukri
Amir Muhaimin Akmal Shukri
JSJeyanthi Suppiah
Jeyanthi Suppiah
RZRozainanee Mohd Zain
Rozainanee Mohd Zain
SWSeok Mui Wang
Seok Mui Wang
Dengue virus (DENV) poses a significant global health burden, with current treatments being limited and primarily supportive. Aptamers are an emerging class of molecular recognition elements that are cheaper, less immunogenic and have no batch-to-batch variation as compared to antibodies. In light of their advantages, aptamers can potentially offer a novel approach to counteract DENV by targeting viral proteins or host factors essential for viral replication and pathogenesis. This review gleans the recent advancements in the development of aptamer-based therapeutic agents targeting dengue virus infection. The latest advancement on aptamers targeting specific dengue virus components such as capsid protein (C), envelope domain III (E3), and nonstructural proteins (NS); and their roles in inhibiting viral replication are highlighted. Although the development of aptamers as potential therapeutics for dengue infections is still in its early stages, based on their therapeutic potentiality, they hold immense potential for dengue viral treatment.